DALLAS, Texas, May 23, 2024 (GLOBE NEWSWIRE) — Mango Ceuticals, Inc. (NASDAQ: MGRX) (“Mango RxMen's Health Products Development Co., Ltd. (hereinafter “the Company”) is a company focused on the development, marketing, and sales of a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, hormone replacement therapy, and weight loss. ) is pleased to announce that we have signed with Crakmedia, a renowned international performance marketing company, to power our ongoing creative and digital marketing efforts.
Based in Quebec City, Canada, Crackmedia is a leader in performance marketing, web development, and traffic monetization. Digital ads on the Crackmedia network are viewed up to 1.5 billion times a day in more than 150 countries and territories. The Company also uses a Crakmedia-owned and operated cost-per-acquisition (CPA) network to manage its affiliate marketing programs. MangoRx can leverage his 15 years of experience in traffic monetization and digital marketing for CPA platforms, as well as over 30 industry awards and nominations.
“We are very fortunate to be working with Crakmedia as we embark on the next phase of significantly increasing our sales efforts and marketing our current and future products,” said Jacob Cohen, co-founder and CEO of MangoRx. I commented. “With over 150 dedicated employees, Crackmedia has a highly successful track record in marketing direct-to-consumer (DTC) companies in men's health and wellness. We believe that Crakmedia's complex industry knowledge and experience will give MangoRx an advantage over its competitors as we continue to add more products and seek to significantly increase revenue.”
With an affiliate platform that maintains exclusive partnerships with some of the world's most innovative brands, Crakmedia strives to provide its partners with superior support and performance marketing solutions. MangoRx also expects uncompromising efficiency through Crakmedia's dedicated compliance team, AI-powered affiliate identity verification, automated compliance testing, and fraud monitoring systems.
“Since launching their products in 2021, MangoRx has answered a real need in the health and wellness industry, and we are thrilled to partner with such an incredible, innovative brand,” said Olivier Bouchard, COO of Crakmedia. “By combining our experience in effectively marketing similar telehealth services with MangoRx's innovative formulas, products and brand voice, we are confident that Crakmedia will enable MangoRx to take the next step in acquiring new customers and continuing to grow.”
About MangoRx
MangoRx is focused on developing a range of men's health products and services through its secure telehealth platform. To date, the company has identified men's health telehealth services and products as growth areas, particularly related to the areas of erectile dysfunction (ED), hair growth, and hormone replacement therapy. Interested consumers can have a smooth experience using MangoRx's telehealth platform. Prescription requests are reviewed by a physician and, if approved, are discreetly shipped through MangoRx's partner pharmacies and delivered directly to the patient's doorstep. To learn more about MangoRx's mission and other products, please visit the website at: Mango Rx or on social media @Mango.Rx.
About Kuraku Media
Crakmedia is a world leader in web marketing, performance marketing, web development and traffic monetization, an international company based in Quebec City. Its areas of activity include digital content design, campaign personalization, website and data analysis, brand management, search engine optimization, media buying, advertising mediation, web development and innovative technology creation. For more information: crack media
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent our current expectations or beliefs regarding future events and can generally be identified by the use of statements containing words such as “estimates,” “expects,” “projects,” “believes,” “anticipates,” “intends,” “projects,” “projects,” “plans,” “projects,” “forecasts,” “likely,” “scheduled,” “target,” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are beyond our control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are beyond our control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, the following: minimum bid price requirements; our stockholders' equity at the end of our next fiscal quarter; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain a Federal Protective Commission for our ED products in Mexico, the costs and timing thereof; and our ability to obtain additional funding and generate revenue to support our operations. There are no risks associated with our ED products, which have not been and will not be approved by the U.S. Food and Drug Administration (“F.D.A.) and do not benefit from the FDA's clinical trial protocols, which aim to prevent the possibility of serious injury or death to patients;FFDCA law”) as provided by Section 503A. risks associated with related party relationships and contracts; data security breaches, malicious code, and/or hacker effects; our ability to generate competition and well-known brand names; Changes in consumer tastes and preferences. material changes and/or termination of relationships with key parties; Critical product returns from customers, product liability, recalls and litigation related to contaminated products or products found to pose health problems. our ability to innovate, expand our offerings and compete with competitors with greater resources; our reliance on related party transactions; the estimated size of the potential market for our technology and products; risks related to the fact that Jacob D. Cohen, our Chairman and Chief Executive Officer, has significant voting power in our company; risks related to the large number of public offerings, the volume of our stock, the impact of the sale of a significant number of our shares in the market and the fact that a majority of our stockholders paid less for their shares than the offering price; recent initial public offerings; Our common stock in . Dilution from recent product offerings. the conversion of outstanding shares of preferred stock and the rights and preferences thereof; the fact that we have a number of outstanding warrants to purchase common stock at $1.00 per share; the resale of the underlying stock; Registered under the U.S. Securities Act. 1933, revised. our ability to build and maintain our brand; CYBERSECURITY, INFORMATION SYSTEMS, FRAUD RISKS AND PROBLEMS WITH OUR WEBSITE. changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations with which we must comply in connection with our operations, manufacturing, labeling and shipping; our dependence on third parties for the formulation and formulation of our ED products; our ability to establish or maintain relationships and/or relationships with third parties; potential safety risks associated with our Mango ED products, including the use of raw materials, the combination of such raw materials and their dosage; changes in inflation rates and interest rates, the effects of economic downturns (including a potential recession), macroeconomic, geopolitical, health and industrial trends, pandemics, acts of war (the ongoing Ukraine/Russia conflict and the war in Israel); ) and other large-scale crises. our ability to protect our intellectual property rights; our ability to attract and retain key personnel to effectively manage our business; overhangs that could reduce the value of our common stock; volatility in the trading price of our common stock; general consumer sentiment and economic conditions that may impact the level of customer discretionary purchases of our products, such as a potential economic recession or global economic slowdown; Although we believe that our plans, intentions and expectations reflected in or implied by the forward-looking statements we make in this release are reasonable, we cannot guarantee that these plans, intentions and expectations will be achieved. there is no. Accordingly, such list should not be considered a complete compilation of all potential risks and uncertainties.
More information on potential factors that could affect our financial results is included from time to time in the “Cautionary Statement on Forward-Looking Statements,” “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024. These filings are available at: www.sec.gov Our Website https://www.mangoceuticals.com/sec-filingsAll subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Other unknown or unpredictable factors could also have a material adverse effect on our future results. The forward-looking statements contained in this press release are made only as of the date hereof. We cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not place undue reliance on these forward-looking statements. Finally, we assume no obligation to update these statements after the date of this release, except as required by law, and we are under no obligation to update or amend information prepared by third parties not paid by us. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or any other forward-looking statements.
Follow Mangoceuticals and MangoRx on social media.
https://www.instagram.com/mango.rx
https://twitter.com/MangoCeuticals
https://www.facebook.com/MangoRxOfficial
PR for investors
Mangoceuticals Investor Information
Email: Investor Relations
sauce: Mango Ceuticals Co., Ltd.
